Total Payments
$1,920
2024 Payments
$194.90
Companies
24
Transactions
108
Medicare Patients
4,364
Medicare Billing
$404,708
Payment Breakdown by Category
Food & Beverage$1,770 (92.2%)
Education$149.99 (7.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,770 | 105 | 92.2% |
| Education | $149.99 | 3 | 7.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $306.66 | 10 | $0 (2017) |
| ABBVIE INC. | $288.76 | 15 | $0 (2024) |
| GlaxoSmithKline, LLC. | $285.03 | 20 | $0 (2024) |
| PFIZER INC. | $166.21 | 11 | $0 (2024) |
| Novo Nordisk Inc | $136.19 | 8 | $0 (2024) |
| Astellas Pharma US Inc | $121.09 | 2 | $0 (2023) |
| Amgen Inc. | $108.05 | 7 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $88.18 | 7 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $70.55 | 5 | $0 (2024) |
| Currax Pharmaceuticals LLC | $50.00 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $194.90 | 10 | ABBVIE INC. ($89.16) |
| 2023 | $546.23 | 26 | ABBVIE INC. ($199.60) |
| 2022 | $83.74 | 6 | GlaxoSmithKline, LLC. ($67.90) |
| 2021 | $137.59 | 9 | GlaxoSmithKline, LLC. ($59.87) |
| 2020 | $243.46 | 16 | PFIZER INC. ($73.62) |
| 2019 | $191.19 | 14 | Janssen Pharmaceuticals, Inc ($65.03) |
| 2018 | $105.94 | 8 | Novo Nordisk Inc ($44.55) |
| 2017 | $416.74 | 19 | Sunovion Pharmaceuticals Inc. ($306.66) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: RESPIRATORY | ||||||
| 09/05/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: Diabetes | ||||||
| 08/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $20.96 | General |
| 07/16/2024 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: RESPIRATORY | ||||||
| 05/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.06 | General |
| Category: NEUROSCIENCE | ||||||
| 05/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Diabetes | ||||||
| 05/01/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: VACCINES | ||||||
| 04/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX, AREXVY | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: RESPIRATORY | ||||||
| 11/20/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX, AREXVY | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2023 | Currax Pharmaceuticals LLC | NEXLETOL (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: Cholesterol Reducer | ||||||
| 11/07/2023 | Currax Pharmaceuticals LLC | NEXLETOL (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: Cholesterol Reducer | ||||||
| 10/31/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: NEUROSCIENCE | ||||||
| 09/25/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: Endocrinology | ||||||
| 09/12/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX, AREXVY | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: RESPIRATORY | ||||||
| 09/07/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Diabetes | ||||||
| 08/21/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: NEUROSCIENCE | ||||||
| 08/18/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: Biological | ||||||
| 08/17/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.45 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 860 | 1,808 | $166,678 | $100,847 |
| 2022 | 11 | 1,018 | 2,032 | $190,067 | $83,840 |
| 2021 | 17 | 1,250 | 2,443 | $245,138 | $116,787 |
| 2020 | 13 | 1,236 | 2,371 | $245,682 | $103,234 |
Total Patients
4,364
Total Services
8,654
Medicare Billing
$404,708
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 435 | 1,068 | $108,570 | $64,977 | 59.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 280 | 587 | $41,450 | $24,855 | 60.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 43 | 48 | $8,400 | $4,858 | 57.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 37 | 37 | $4,070 | $3,989 | 98.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $1,848 | $1,043 | 56.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 18 | 21 | $1,218 | $624.90 | 51.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 17 | 17 | $798.00 | $415.20 | 52.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 18 | 18 | $324.00 | $84.14 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 499 | 1,262 | $128,206 | $54,507 | 42.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 271 | 487 | $34,060 | $18,264 | 53.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 76 | 76 | $8,424 | $3,564 | 42.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $6,160 | $3,286 | 53.3% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 53 | 54 | $9,450 | $2,528 | 26.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 15 | 23 | $1,334 | $740.91 | 55.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 14 | 16 | $1,020 | $507.29 | 49.7% |
| 69210 | Removal of impacted ear wax | Office | 2022 | 11 | 11 | $341.00 | $192.98 | 56.6% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 13 | 13 | $546.00 | $117.61 | 21.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 15 | 16 | $288.00 | $86.28 | 30.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 11 | 34 | $238.00 | $46.56 | 19.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 129 | 544 | $52,768 | $28,388 | 53.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 347 | 669 | $68,434 | $28,238 | 41.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 304 | 639 | $44,750 | $18,381 | 41.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 87 | 123 | $23,985 | $11,842 | 49.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 103 | 162 | $15,552 | $8,406 | 54.1% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2021 | 58 | 70 | $12,250 | $7,520 | 61.4% |
About Dr. Daniel Pace, MD
Dr. Daniel Pace, MD is a Family Medicine healthcare provider based in Searcy, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972567758.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Pace, MD has received a total of $1,920 in payments from pharmaceutical and medical device companies, with $194.90 received in 2024. These payments were reported across 108 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,770).
As a Medicare-enrolled provider, Pace has provided services to 4,364 Medicare beneficiaries, totaling 8,654 services with total Medicare billing of $404,708. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Searcy, AR
- Active Since 04/17/2006
- Last Updated 09/24/2012
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1972567758
Products in Payments
- VRAYLAR (Drug) $262.81
- BROVANA (Drug) $256.84
- TRELEGY ELLIPTA (Drug) $209.05
- Ozempic (Drug) $108.10
- CHANTIX (Drug) $100.60
- EVENITY (Biological) $66.50
- INVOKANA (Drug) $65.03
- ANORO ELLIPTA (Drug) $64.53
- NEXLETOL (Drug) $50.00
- LATUDA (Drug) $49.82
- JARDIANCE (Drug) $49.59
- PREVNAR 20 (Biological) $41.07
- UBRELVY (Drug) $38.77
- Victoza (Drug) $28.09
- Dayvigo (Drug) $27.89
- EMGALITY (Drug) $25.73
- GLASSIA (Biological) $24.39
- XARELTO (Drug) $23.15
- Veozah (Drug) $21.10
- INTELLIS ADAPTIVESTIM (Device) $20.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Searcy
Dr. Joseph Reardon, Md, MD
Family Medicine — Payments: $17,045
Family Medicine $17,045
Dr. John Duke, M.d, M.D
Family Medicine — Payments: $6,856
Family Medicine $6,856
Nicole Lawson, Md, MD
Family Medicine — Payments: $2,699
Family Medicine $2,699
Dr. Michael Barden, M.d,, M.D,
Family Medicine — Payments: $1,495
Family Medicine $1,495
John Wornock, Md, MD
Family Medicine — Payments: $1,307
Family Medicine $1,307
Joseph Dugger, Md, MD
Family Medicine — Payments: $1,294
Family Medicine $1,294